■ Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)
Ligia Yukie Sassaki, Daniela Oliveira Magro, Rogerio Saad-Hossne et al
GEDIIB (Brazilian Study Group of IBD)
BMC Gastroenterol. 2022; 22: 268
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150299/
■ Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis fator patients with Crohn´s disease: a real-world multicenter Brazilian study
Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Natália Sousa Freitas Queiroz et al
BMC Gastroenterol. 2022; 22: 199.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027080/
■ Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agente after the failure of a first anti-TNF agente in patients with Crohn´s disease: a multicenter rerospective study
Rayer Cassandra, Maria Nachury, Bourreille Arnaudet et al
BMC Gastroenterol. 2022; 22: 498
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717550/
■ Female gender, dissatisfaction with weight, and number of IBD related surgeries as independente risk factors for eating disorders among patients with inflammatory bowel diseases
Gianna Stoleru, Andrew Leopold, Amanda Auerbach, Shelley Nehman, Uni Wong
BMC Gastroenterol. 2022; 22: 438
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578268/
■ Real world evidence of the association between medication and life expectancy in elderly inflammatory bowel disease: a population-based cohort study
- Ellen Kuenzig, Douglas G. Manuel, Jessy Donelle, Eric I. Benchimol
BMC Gastroenterol. 2022; 22: 5
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728958/
■ Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with fofacitinib for moderate to severe ulcerative colitis
M V Chiorean, J R Allegretti, P P Sharma et al
BMC Gastroenterol. 2022; 22: 177
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994921/
■ Comparison the effects and side effects of COVID-19 vaccination in patients with inflammatory bowel
l disease (IBD): a systematic scoping review
Elham Tabesh, Maryam Soheilipour, Mohammad Rezaeisadrabadi, et al
BMC Gastroenterol. 2022; 22: 393
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392501/
■ Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe COVID-19 pneumonia: a case report
Lisanne Rieker, Johannes Hofer, Golo Petzold, et al
BMC Gastroenterol. 2022; 22: 22
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760596/
■ Quality assessment of Clinical Practice Guidelines (CPG) for the diagnosis and treatment of inflammatory bowel disease using the AGREE II instrument: a systematic review
- Zambrano-Sánchez, P. Alvarez-Mena, D. Hidalgo, et al
BMC Gastroenterol. 2022; 22: 447
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637309/
■ Ultrasonographic scores for ileal Crohn´s disease assessment: Better, worse or the same as contrast-enhanced ultrasound?
- Freitas, F. Dias de Castro, V. Macedo Silva et al
BMC Gastroenterol. 2022; 22: 252
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118849/
■ Physical activity measured by accelerometry in paediatric and young adult patients with inflammatory bowel disease
Ken Lund, Michael Due Larsen, Torben Knudsen et al
BMC Gastroenterol. 2022; 22: 290
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171971/
■ Systematic review and meta-analysis: the advantage of endoscopic Mayo score o over 1 in patients with ulcerative colitis
Angelo Viscido, Marco Valvano, Gianpiero Stefanelli, et al
BMC Gastroenterol. 2022; 22: 92
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895505/
■ A systematic review of the patient burden of Crohn´s disease-related rectovaginal and anovaginal fistulas
Kristy Iglay, Dimitri Bennett, Michael D. Kappelman, et al
BMC Gastroenterol. 2022; 22: 36
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796404/
■ Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
Benjamin Click, Edward L. Barnes, Benjamin L. Cohen, et al
BMC Gastroenterol. 2022; 22: 71
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858477/
■ Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methrotrexate accumulation in Crohn´s disease: across-sectional study
- M. van de Meeberg, M. L. Seinen, H. H. Fidder, et al
BMC Gastroenterol. 2022; 22: 365
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338675/
■ Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
V Jairath, R D Cohen, E V Loftus et al
BMC Gastroenterol 2022, vol 22: 501
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724317/
■ Multimorbidity among inflammatory bowel disease patients ina tertiary care centre: a retrospective study
M H Mosli, M Alsahafi, M N Alsanea et al
BMC Gastroenterol 2022, vol 22: 487
https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-022-02578-2
■ Effects of clinical versus administrative data definitions on the epidemiology of C. difficile among hospitalized individuals with IBD: a population-based cohort study
Seth R. Shaffer, Zoann Nugent, Charles N. Bernstein et al
BMC Gastroenterol. 2022; 22: 140
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962161/
■ Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study
Kay-Martin Johnsen, Jon Florholmen, Øystein K. Moe et al
BMC Gastroenterol. 2022; 22: 459
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667633/
■ Multimodal intervention to improve the transition of patients with inflammatory bowel disease from pediatric to adult care: protocol for a randomized controlled trial
Natasha Bollegala, Melanie Barwick, Nancy Fu et al
BMC Gastroenterol. 2022; 22: 251
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118697/
■ Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al
BMC Gastroenterol. 2022; 22: 291
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178865/
■ Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
Rasmus Goll, Øystein K. Moe, Kay-Martin Johnsen, et al
BMC Gastroenterol. 2022; 22: 464
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670620/
■ Medication use among patients with Crohn´s disease or ulcerative colitis before and after the initiation of advanced therapy
Theresa Hunter, April N. Naegeli, Chi Nguyen et al
BMC Gastroenterol. 2022; 22: 474
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675977/
■ Clustering of pediatric onset inflammatory bowel disease in Finland: a Nationwide register-based study
Atte Nikkilä, Anssi Auvinen, Kaija-Leena Kolho
BMC Gastroenterol. 2022; 22: 512
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743626/
■ Clustering of pediatric onset inflammatory bowel disease in Finland: a Nationwide register-based study
Atte Nikkilä, Anssi Auvinen, Kaija-Leena Kolho
BMC Gastroenterol. 2022; 22: 512
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743626/
■ Intestinal fatty acid binding protein is a disease biomarker in paediatric coeliac disease and Cronh´s disease
Michael Logan, Mary MacKinder, Clare Martha Clark et al
BMC Gastroenterol. 2022; 22: 260
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125891/
■ Emphysematous cystitis as a potential marker of severe Crohn´s disease
- M. Mahmudul Hasan, Baljinder S. Salh
BMC Gastroenterol. 2022; 22: 181
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004142/
■ A case for improved assessment of gut permeability: a meta-analysis quantifying the lactulose: manitol ratio in coeliac and Crohn´s disease
Jonathan Gan, Scarlet Nazarian, Julian Teare, et al
BMC Gastroenterol. 2022; 22: 16
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751358/
■ Acesso gratuito
■ Um dos Blog de Medicina mais acessado em todo o mundo. Mais de 810 temas médicos já disponíveis online
■ Use o mecanismo de busca – PESQUISAR na home page.
■ Acesse ARQUIVO e encontre os temas incluídos no Blog a cada mês, desde maio 2017
■ Blog Internet Médica – www.internetmedica.com.br
■ Médico Responsável: Dr Paulo Fernando Leite
CRMMG: 7026
Belo Horizonte/MG/Brasil
Email: pfleite1873@gmail.com
Março 2023